Lunsumio
What Lunsumio is used for
Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Lunsumio
- Active substance
- mosunetuzumab
- Disease area
- Lymphoma, Follicular
- Medicine group
- Antineoplastic agents;monoclonal antibodies and antibody drug conjugates
- ATC code
- L01FX25
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Lunsumio Velo, Lunsumio
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lunsumio used for?
Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
What is the active substance in Lunsumio?
Lunsumio contains mosunetuzumab.
Who makes Lunsumio?
The EU marketing authorisation holder is Roche Registration GmbH.
Is Lunsumio an orphan medicine?
Yes. Lunsumio is designated an orphan medicine in the EU, for a rare disease (Lymphoma, Follicular).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU